Published in Gut on April 29, 2005
Multilocus sequence typing reveals intrafamilial transmission and microevolutions of Candida albicans isolates from the human digestive tract. J Clin Microbiol (2006) 1.34
Current and future role of biomarkers in Crohn's disease risk assessment and treatment. Clin Exp Gastroenterol (2011) 0.86
Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn's disease: a meta-analysis. Dig Dis Sci (2012) 0.85
Diagnostic and Prognostic Microbial Biomarkers in Inflammatory Bowel Diseases. Gastroenterology (2015) 0.82
Immunogenetic phenotypes in inflammatory bowel disease. World J Gastroenterol (2006) 0.80
Serologic investigations in children with inflammatory bowel disease and food allergy. Mediators Inflamm (2009) 0.78
Association of levels of antibodies from patients with inflammatory bowel disease with extracellular proteins of food and probiotic bacteria. Biomed Res Int (2014) 0.77
Serological markers (anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic antibodies) in inflammatory bowel disease: diagnostic utility and phenotypic correlation. Clin Diagn Lab Immunol (2005) 0.76
Diagnostic Value of ASCA and Atypical p-ANCA in Differential Diagnosis of Inflammatory Bowel Disease. Middle East J Dig Dis (2013) 0.75
Antibody markers in the diagnosis of inflammatory bowel disease. World J Gastroenterol (2016) 0.75
Host-microbiome interaction in Crohn's disease: A familiar or familial issue? World J Gastrointest Pathophysiol (2015) 0.75
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 33.12
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature (2001) 28.24
A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis (2000) 6.90
The Swedish Twin Registry: a unique resource for clinical, epidemiological and genetic studies. J Intern Med (2002) 5.37
CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet (2002) 5.31
Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology (2004) 4.42
The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology (2002) 4.20
The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology (2002) 4.20
The use of transformation when comparing two means. BMJ (1996) 3.22
Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease. Gut (2000) 2.71
Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology (2002) 2.66
Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology (2003) 2.64
Studies on similarity diagnosis in twins with the aid of mailed questionnaires. Acta Genet Stat Med (1961) 2.61
Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology (2003) 2.57
Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut (2000) 2.47
Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology (1998) 2.38
Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. BMJ (1988) 2.28
A novel NOD2/CARD15 haplotype conferring risk for Crohn disease in Ashkenazi Jews. Am J Hum Genet (2003) 2.17
Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet (2002) 2.12
Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol (2001) 2.06
Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol (1998) 2.03
NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe? Genes Immun (2004) 1.94
Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol (1996) 1.89
CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease. Gut (2003) 1.87
CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet (2002) 1.74
Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis (2001) 1.41
Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology (2004) 1.38
Genetic variants of the mannan-binding lectin are associated with immune reactivity to mannans in Crohn's disease. Gastroenterology (2004) 1.38
Transmission of CARD15 (NOD2) variants within families of patients with inflammatory bowel disease. Am J Gastroenterol (2004) 1.32
IBD: a family affair. Best Pract Res Clin Gastroenterol (2004) 1.29
Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol (2004) 1.26
The c-insertion mutation of the NOD2 gene is associated with fistulizing and fibrostenotic phenotypes in Crohn's disease. Gastroenterology (2002) 1.20
NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology (2002) 1.20
Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family study. Scand J Gastroenterol (2001) 1.15
Variation at NOD2/CARD15 in familial and sporadic cases of Crohn's disease in the Ashkenazi Jewish population. Am J Gastroenterol (2002) 0.87
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 33.12
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis (2010) 6.75
Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature (1996) 5.44
Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology (1998) 5.02
Dysbiosis in inflammatory bowel disease. Gut (2004) 5.01
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis (2009) 3.22
Appendectomy and protection against ulcerative colitis. N Engl J Med (2001) 3.06
No resuscitation orders and withdrawal of therapy in French paediatric intensive care units. Groupe Francophone de Réanimation et d'Urgences Pédiatriques. Acta Paediatr (1998) 2.86
Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients. Gut (1996) 2.79
Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod (2011) 2.71
Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects. Am Rev Respir Dis (1992) 2.55
Microscopic colitis: a common diarrhoeal disease. An epidemiological study in Orebro, Sweden, 1993-1998. Gut (2004) 2.48
Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther (2010) 2.47
Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology (1995) 2.47
Collagenous colitis and fecal stream diversion. Gastroenterology (1995) 2.32
Genetic analyses of chromosome 12 loci in Crohn's disease. Gut (2000) 2.30
Endoscopic dilation is an efficacious and safe treatment of intestinal strictures in Crohn's disease. Aliment Pharmacol Ther (2012) 2.29
Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect Immun (2001) 2.28
Risk factors and clinical relevance of nosocomial maxillary sinusitis in the critically ill. Am J Respir Crit Care Med (1994) 2.19
Can severity-of-illness indices for neonatal intensive care predict outcome at 4 years of age? Acta Paediatr (2002) 2.16
An in-depth study of Crohn's disease in two French families. Gastroenterology (1993) 2.15
European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis (2008) 2.14
Smoking is a risk factor for recurrence of intestinal stricture after endoscopic dilation in Crohn's disease. Aliment Pharmacol Ther (2012) 2.07
Long-term prognosis of clinical symptoms and health-related quality of life in microscopic colitis: a case-control study. Aliment Pharmacol Ther (2014) 2.05
Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. Aliment Pharmacol Ther (2013) 2.05
Early predictors of death and disability after acute cerebral ischemic event. Stroke (1995) 2.04
Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol (1998) 2.03
Different intestinal permeability patterns in relatives and spouses of patients with Crohn's disease: an inherited defect in mucosal defence? Gut (1999) 2.01
Incidence of Helicobacter pylori strains activating neutrophils in patients with peptic ulcer disease. Gut (1993) 1.99
Epidemiologic study of sleep quality and troubles in French secondary school adolescents. J Adolesc Health (1997) 1.98
Dysbiosis as a prerequisite for IBD. Gut (2004) 1.93
Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology (1991) 1.93
Tobacco smoke exposure and pregnancy outcome among working women. A prospective study at prenatal care centers in Orebro County, Sweden. Am J Epidemiol (1991) 1.92
Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol (1996) 1.89
Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease. J Exp Med (1992) 1.88
Duodenal intraepithelial lymphocyte-count revisited. Scand J Gastroenterol (2004) 1.88
Smoking in Crohn's disease: effect on localisation and clinical course. Gut (1992) 1.87
Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis. Br J Surg (2012) 1.84
Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol (2000) 1.82
Programmes to reduce pelvic inflammatory disease--the Swedish experience. Lancet (1998) 1.81
Incidence of inflammatory bowel disease in northern France (1988-1990). Gut (1994) 1.81
Systematic review: microscopic colitis. Aliment Pharmacol Ther (2006) 1.81
Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. Gastroenterology (1986) 1.80
Decreasing incidences of gonorrhea- and chlamydia-associated acute pelvic inflammatory disease. A 25-year study from an urban area of central Sweden. Sex Transm Dis (1997) 1.79
Antigenic variability of Candida albicans. Crit Rev Microbiol (1985) 1.79
Neuropsychological test results and symptoms among workers with well-defined long-term exposure to lead. Br J Ind Med (1983) 1.73
Interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 in eosinophilic gastroenteritis. Gastroenterology (1996) 1.73
Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID) Gastroenterology (1993) 1.71
Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol (2000) 1.69
Smoking and inflammatory bowel disease. A case control study. Gut (1988) 1.69
Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology (1997) 1.69
Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology (1999) 1.68
Helical CT angiography of thoracic outlet syndrome: functional anatomy. AJR Am J Roentgenol (2000) 1.68
Preliminary clinical study using a multiplex real-time PCR test for the detection of bacterial and fungal DNA directly in blood. Clin Microbiol Infect (2009) 1.67
Treatment of diversion colitis by short-chain fatty acids. Prospective and double-blind study. Dis Colon Rectum (1991) 1.65
Collagenous colitis in Orebro, Sweden, an epidemiological study 1984-1993. Gut (1995) 1.64
Familial occurrence of microscopic colitis: a report on five families. Scand J Gastroenterol (2001) 1.64
Enterocolitis induced by autoimmune targeting of enteric glial cells: a possible mechanism in Crohn's disease? Proc Natl Acad Sci U S A (2001) 1.63
Latent pulmonary involvement in Crohn's disease: biological, functional, bronchoalveolar lavage and scintigraphic studies. Gut (1986) 1.63
Histologic aspects of pulmonary barotrauma in critically ill patients with acute respiratory failure. Intensive Care Med (1993) 1.63
Peripheral pulmonary arteries: optimization of the spiral CT acquisition protocol. Radiology (1997) 1.62
Genetically related Escherichia coli strains associated with Crohn's disease. Gut (2001) 1.61
Comparative study of split thickness skin grafts taken from the scalp and thigh in children. Burns (1994) 1.60
Inflammatory bowel disease in married couples: 10 cases in Nord Pas de Calais region of France and Liège county of Belgium. Gut (1994) 1.57
Low circulating insulin-like growth factor I in coeliac disease and its relation to bone mineral density. Scand J Gastroenterol (1999) 1.56
Microscopic colitis: Current status, present and future challenges: statements of the European Microscopic Colitis Group. J Crohns Colitis (2012) 1.56
Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients. Gut (2004) 1.56
Perioperative endoscopy of the whole small bowel in Crohn's disease. Gut (1993) 1.54
Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine? Lancet (1994) 1.53
Mapping of Candida albicans oligomannosidic epitopes by using monoclonal antibodies. Infect Immun (1992) 1.52
Mutation in bone morphogenetic protein receptor-IB is associated with increased ovulation rate in Booroola Mérino ewes. Proc Natl Acad Sci U S A (2001) 1.51
Association between myelodysplastic syndromes and inflammatory bowel diseases. Report of seven new cases and review of the literature. Leukemia (1997) 1.50
Colonoscopy during an attack of severe ulcerative colitis is a safe procedure and of great value in clinical decision making. Am J Gastroenterol (1991) 1.50
Relation between concentrations of metronidazole and Bacteroides spp in faeces of patients with Crohn's disease and healthy individuals. J Clin Pathol (1981) 1.49
Neuropsychological abnormalities in first degree relatives of patients with familial Parkinson's disease. J Neurol Neurosurg Psychiatry (1999) 1.47
A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology (1982) 1.46
New enzyme immunoassays for sensitive detection of circulating Candida albicans mannan and antimannan antibodies: useful combined test for diagnosis of systemic candidiasis. J Clin Microbiol (1999) 1.46
[112 cases of sporadic and genetically determined pheochromocytoma: a comparative pathologic study]. Ann Pathol (1999) 1.44
Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis (2001) 1.44